• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖皮质激素性骨质疏松症防治的新共识

Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis.

作者信息

Compston Juliet E

机构信息

University of Cambridge School of Clinical Medicine, and Addenbrooke's Hospital, Box 157, Cambridge CB2 2QQ, UK.

出版信息

Curr Rheumatol Rep. 2007 Apr;9(1):78-84. doi: 10.1007/s11926-007-0026-x.

DOI:10.1007/s11926-007-0026-x
PMID:17437672
Abstract

Glucocorticoid-induced osteoporosis is a common but still relatively neglected problem, with a low level of awareness among primary and secondary care physicians. Fractures appear early after initiation of treatment, and effective prophylaxis requires primary prevention in those at high risk of fracture. Bisphosphonates are the treatment of choice, and calcium and vitamin D supplements are also indicated in the majority of individuals. Organized care programs together with the use of evidence-based guidelines have the potential to improve significantly the management of this serious complication of glucocorticoid therapy.

摘要

糖皮质激素诱导的骨质疏松症是一个常见但仍相对被忽视的问题,基层和二级医疗保健医生对此的认识水平较低。骨折在开始治疗后不久就会出现,有效的预防需要对骨折高危人群进行一级预防。双膦酸盐是首选治疗药物,大多数患者也需要补充钙和维生素D。有组织的护理计划以及使用循证指南有可能显著改善糖皮质激素治疗这一严重并发症的管理。

相似文献

1
Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis.糖皮质激素性骨质疏松症防治的新共识
Curr Rheumatol Rep. 2007 Apr;9(1):78-84. doi: 10.1007/s11926-007-0026-x.
2
How to prevent glucocorticoid-induced osteoporosis.如何预防糖皮质激素性骨质疏松症。
Cleve Clin J Med. 2010 Aug;77(8):529-36. doi: 10.3949/ccjm.77a.10003.
3
[Glucocorticoid-induced osteoporosis : treatment update].[糖皮质激素性骨质疏松症:治疗进展]
Clin Calcium. 2012 Feb;22(2):229-35.
4
Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis.继发性骨质疏松症:潜在疾病与糖皮质激素诱导的骨质疏松症风险
Clin Ther. 2004 Jan;26(1):1-14. doi: 10.1016/s0149-2918(04)90001-x.
5
[Therapy of glucocorticoid induced osteoporosis].[糖皮质激素性骨质疏松症的治疗]
G Ital Nefrol. 2017 Dec 5;34(Nov-Dec):2017-vol6.
6
[Glucocorticoid induced osteoporosis].[糖皮质激素性骨质疏松症]
Orthopade. 2007 Apr;36(4):381-8; quiz 389-90.
7
Clinical practice. Glucocorticoid-induced bone disease.临床实践。糖皮质激素诱导的骨病
N Engl J Med. 2011 Jul 7;365(1):62-70. doi: 10.1056/NEJMcp1012926.
8
[Secondary osteoporosis. Glucocorticoid induced osteoporosis in childhood : prophylaxis and treatment].[继发性骨质疏松症。儿童糖皮质激素诱导的骨质疏松症:预防与治疗]
Clin Calcium. 2007 Jul;17(7):1114-9.
9
Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice.日常皮肤科实践中糖皮质激素诱导性骨质疏松症的防治
Int J Dermatol. 2008 Jul;47(7):737-42. doi: 10.1111/j.1365-4632.2008.03679.x.
10
Glucocorticoid induced osteoporosis.糖皮质激素性骨质疏松症
Expert Rev Endocrinol Metab. 2019 Jul;14(4):259-266. doi: 10.1080/17446651.2019.1617131. Epub 2019 May 16.

引用本文的文献

1
Prednisolone induces osteocytes apoptosis by promoting Notum expression and inhibiting PI3K/AKT/GSK3β/β-catenin pathway.泼尼松龙通过促进 Notum 表达和抑制 PI3K/AKT/GSK3β/β-catenin 通路诱导成骨细胞凋亡。
J Mol Histol. 2021 Oct;52(5):1081-1095. doi: 10.1007/s10735-021-10006-0. Epub 2021 Jul 23.
2
Technetium-99 Conjugated with Methylene Diphosphonate Ameliorates Glucocorticoid Induced Osteoporosis by Inhibiting Osteoclastogenesis.锝[99mTc]亚甲基二膦酸盐通过抑制破骨细胞生成改善糖皮质激素诱导的骨质疏松症。
Biomed Res Int. 2018 Oct 14;2018:7902760. doi: 10.1155/2018/7902760. eCollection 2018.
3
Autophagy as a target for glucocorticoid-induced osteoporosis therapy.

本文引用的文献

1
Review and evaluation of the Dutch guidelines for osteoporosis.荷兰骨质疏松症指南的回顾与评估。
J Eval Clin Pract. 2006 Oct;12(5):539-48. doi: 10.1111/j.1365-2753.2006.00647.x.
2
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.阿仑膦酸钠或阿法骨化醇治疗糖皮质激素诱导的骨质疏松症。
N Engl J Med. 2006 Aug 17;355(7):675-84. doi: 10.1056/NEJMoa053569.
3
Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year.糖皮质激素诱导的骨质疏松症项目(GIOP):一个新颖、全面且非常成功的护理项目,在1年内改善了治疗效果。
自噬作为糖皮质激素诱导性骨质疏松症治疗的靶点。
Cell Mol Life Sci. 2018 Aug;75(15):2683-2693. doi: 10.1007/s00018-018-2776-1. Epub 2018 Feb 9.
4
A review of the use of dual-energy X-ray absorptiometry (DXA) in rheumatology.双能X线吸收测定法(DXA)在风湿病学中的应用综述。
Open Access Rheumatol. 2012 Dec 11;4:99-107. doi: 10.2147/OARRR.S29000. eCollection 2012.
5
Glucocorticoid-induced osteoporosis: who to treat with what agent?糖皮质激素性骨质疏松症:用什么药物治疗谁?
Nat Rev Rheumatol. 2015 Feb;11(2):98-109. doi: 10.1038/nrrheum.2014.188. Epub 2014 Nov 11.
6
Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?糖皮质激素诱导的骨质疏松症的相关建议是否足以确定类风湿性关节炎患者的抗骨质疏松治疗方案?
Korean J Intern Med. 2014 Jul;29(4):509-15. doi: 10.3904/kjim.2014.29.4.509. Epub 2014 Jun 27.
7
Treatment of glucocorticoid-induced osteoporsis.糖皮质激素性骨质疏松症的治疗。
Ther Adv Musculoskelet Dis. 2009 Feb;1(1):27-34. doi: 10.1177/1759720X09343222.
8
Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study.预防糖皮质激素性骨质疏松症的方法:来自意大利多中心观察性 EGEO 研究的结果。
J Endocrinol Invest. 2013 Feb;36(2):92-6. doi: 10.3275/8288. Epub 2012 Mar 6.
9
A reappraisal of generic bisphosphonates in osteoporosis.重新评价骨质疏松症中的通用双膦酸盐。
Osteoporos Int. 2012 Jan;23(1):213-21. doi: 10.1007/s00198-011-1796-6. Epub 2011 Sep 28.
10
Osteoporosis-related simultaneous four joints fractures and dislocation after a seizure: a case report.癫痫发作后骨质疏松相关的同时性四关节骨折与脱位:一例报告
J Osteoporos. 2010 Mar 3;2010:808341. doi: 10.4061/2010/808341.
Osteoporos Int. 2006;17(9):1428-34. doi: 10.1007/s00198-006-0149-3. Epub 2006 Jun 1.
4
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.慢性糖皮质激素使用者对阿仑膦酸盐和利塞膦酸盐的使用情况及依从性
Osteoporos Int. 2006;17(8):1268-74. doi: 10.1007/s00198-006-0136-8. Epub 2006 May 19.
5
Glucocorticoid-induced osteoporosis: an update.糖皮质激素性骨质疏松症:最新进展
Trends Endocrinol Metab. 2006 May-Jun;17(4):144-9. doi: 10.1016/j.tem.2006.03.009.
6
Glucocorticoid-induced osteoporosis and its treatment.糖皮质激素性骨质疏松症及其治疗
Clin Orthop Relat Res. 2006 Feb;443:39-47. doi: 10.1097/01.blo.0000200238.29931.1f.
7
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.糖皮质激素性骨质疏松症防治的循证指南:比利时骨科学会共识文件
Osteoporos Int. 2006 Jan;17(1):8-19. doi: 10.1007/s00198-005-2032-z. Epub 2005 Oct 11.
8
Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis.患者关于糖皮质激素性骨质疏松症预防和治疗的知识、信念及行为。
Arthritis Rheum. 2005 Oct 15;53(5):732-9. doi: 10.1002/art.21446.
9
Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.阿法骨化醇与普通维生素D治疗糖皮质激素/炎症诱导的骨质疏松症的比较
J Rheumatol Suppl. 2005 Sep;76:33-40.
10
Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.糖皮质激素性骨质疏松症高危患者的实践模式
Osteoporos Int. 2005 Dec;16(12):2168-74. doi: 10.1007/s00198-005-2016-z. Epub 2005 Sep 3.